XOMA Corporation
Index- P/E- EPS (ttm)-1.98 Insider Own0.20% Shs Outstand11.46M Perf Week-6.91%
Market Cap237.05M Forward P/E- EPS next Y-0.34 Insider Trans194.25% Shs Float11.38M Perf Month-10.05%
Income-22.60M PEG- EPS next Q-0.49 Inst Own59.10% Short Float / Ratio3.85% / 14.60 Perf Quarter3.48%
Sales6.00M P/S39.51 EPS this Y-402.70% Inst Trans0.88% Short Interest0.44M Perf Half Y4.04%
Book/sh10.82 P/B1.81 EPS next Y64.60% ROA-14.40% Target Price62.50 Perf Year-35.12%
Cash/sh6.52 P/C3.01 EPS next 5Y19.00% ROE-16.50% 52W Range15.68 - 32.08 Perf YTD4.38%
Dividend- P/FCF- EPS past 5Y-36.40% ROI-14.00% 52W High-40.14% Beta0.84
Dividend %- Quick Ratio14.70 Sales past 5Y-35.20% Gross Margin- 52W Low22.48% ATR1.11
Employees12 Current Ratio14.70 Sales Q/Q-95.80% Oper. Margin- RSI (14)37.79 Volatility5.37% 5.12%
OptionableYes Debt/Eq0.00 EPS Q/Q-138.00% Profit Margin- Rel Volume0.60 Prev Close19.64
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume30.03K Price19.20
Recom2.50 SMA20-9.32% SMA50-9.14% SMA200-3.11% Volume4,869 Change-2.21%
Sep-07-21Downgrade Wedbush Outperform → Neutral $22
Jun-29-21Initiated Aegis Capital Buy $60
Jan-19-21Reiterated H.C. Wainwright Buy $30 → $56
Jan-18-18Reiterated H.C. Wainwright Buy $38 → $49
Oct-17-17Resumed H.C. Wainwright Buy $38
Sep-05-17Upgrade Wedbush Neutral → Outperform $9 → $19
Jun-12-17Initiated H.C. Wainwright Buy $15
Nov-14-16Downgrade Wedbush Outperform → Neutral $17 → $14
Mar-11-16Reiterated Wedbush Outperform $6 → $3
Jul-23-15Downgrade Jefferies Buy → Hold
Show Previous Ratings
Mar-21-23 07:30AM
Mar-10-23 05:36AM
Mar-09-23 07:30AM
Mar-06-23 08:28AM
Feb-28-23 07:30AM
07:00PM Loading…
Jan-06-23 07:00PM
Jan-04-23 07:30AM
Dec-22-22 07:30AM
Dec-07-22 07:44AM
Nov-22-22 07:01AM
Nov-06-22 09:24AM
Nov-03-22 09:05AM
Sep-27-22 08:30AM
Sep-21-22 07:30AM
07:30AM Loading…
Sep-07-22 07:30AM
Sep-01-22 06:20AM
Aug-11-22 06:22AM
Aug-04-22 10:45AM
Jun-30-22 07:33AM
Jun-20-22 07:30AM
Jun-02-22 01:00AM
May-30-22 07:06AM
May-17-22 04:05PM
May-07-22 08:27AM
May-05-22 08:55AM
May-03-22 08:15AM
Apr-20-22 08:24AM
07:30AM Loading…
Mar-21-22 07:30AM
Mar-15-22 06:21AM
Mar-10-22 09:43AM
Mar-08-22 07:30AM
Mar-01-22 07:30AM
Feb-17-22 07:30AM
Jan-21-22 10:21AM
Dec-23-21 07:30AM
Dec-21-21 07:30AM
Dec-16-21 07:30AM
Nov-22-21 11:46AM
Nov-15-21 06:01AM
Nov-04-21 10:15AM
Oct-28-21 03:06PM
Oct-27-21 04:50AM
Oct-14-21 06:57AM
Oct-08-21 03:35AM
Sep-22-21 07:30AM
Sep-21-21 12:33PM
Sep-20-21 07:30AM
Sep-13-21 07:30AM
Sep-07-21 01:49PM
Aug-10-21 04:35PM
Aug-05-21 08:45AM
Jul-29-21 03:05PM
Jul-28-21 07:30AM
Jul-15-21 06:38AM
Jun-23-21 03:16PM
Jun-21-21 07:30AM
Jun-08-21 10:38AM
May-21-21 08:00AM
May-06-21 09:15AM
May-03-21 07:30AM
Apr-15-21 09:05AM
Apr-12-21 07:30AM
Apr-06-21 07:02PM
Apr-05-21 04:05PM
Mar-23-21 08:00AM
Mar-22-21 07:30AM
Mar-10-21 08:45AM
Mar-03-21 05:16AM
Mar-02-21 12:30PM
Feb-23-21 04:05PM
Jan-04-21 04:05PM
Dec-30-20 05:50AM
Dec-21-20 05:00PM
Dec-10-20 11:45PM
Dec-08-20 08:38AM
Nov-16-20 07:30AM
Nov-12-20 09:47AM
Nov-11-20 07:30AM
Nov-06-20 08:56AM
Nov-05-20 09:35AM
Nov-03-20 07:30AM
Oct-28-20 07:30AM
Oct-14-20 07:30AM
Sep-23-20 12:15PM
Sep-10-20 11:18AM
Sep-02-20 07:30AM
XOMA Corporation operates as a biotech royalty aggregator in Europe, the United States, and the Asia Pacific. The company engages in helping biotech companies for enhancing human health. It acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. The company focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners. It has a portfolio with various assets. The company was incorporated in 1981 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BVF PARTNERS L P/ILDirectorJan 06Buy21.983,24971,4191,789,844Jan 09 05:44 PM
BVF PARTNERS L P/ILDirectorJan 05Buy18.3919,000349,3191,788,168Jan 09 05:44 PM
BVF PARTNERS L P/ILDirectorSep 27Buy16.891,68228,4091,784,838Sep 27 07:22 PM
BVF PARTNERS L P/ILDirectorSep 26Buy16.836,360107,0501,783,834Sep 27 07:22 PM
BVF PARTNERS L P/ILDirectorSep 23Buy16.5016,600273,8501,780,495Sep 27 07:22 PM
BVF PARTNERS L P/ILDirectorSep 16Buy17.8924,293434,5361,773,780Sep 16 06:30 PM
BVF PARTNERS L P/ILDirectorSep 15Buy17.965,575100,1381,576,913Sep 16 06:30 PM
BVF PARTNERS L P/ILDirectorSep 14Buy17.2526,441456,0441,571,338Sep 16 06:30 PM
Neal James RCEOJul 15Option Exercise4.0325,000100,75036,822Jul 18 04:30 PM
BURNS THOMAS M.SVP, Finance & CFOJul 15Option Exercise4.032,0008,0608,555Jul 18 04:30 PM
Neal James RCEOJul 15Sale29.8425,000746,10411,822Jul 18 04:30 PM
BURNS THOMAS M.SVP, Finance & CFOJul 15Sale31.662,00063,3216,555Jul 18 04:30 PM
Neal James RCEOMar 23Option Exercise4.031,1114,47712,933Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 23Option Exercise4.031616496,716Mar 23 06:52 PM
Neal James RCEOMar 23Sale30.021,11133,34811,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 23Sale30.001614,8306,555Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 22Option Exercise4.032,3399,4268,894Mar 23 06:52 PM
Neal James RCEOMar 22Option Exercise4.032,3399,42614,161Mar 23 06:52 PM
Neal James RCEOMar 22Sale30.022,33970,20911,822Mar 23 06:52 PM
BURNS THOMAS M.SVP, Finance & CFOMar 22Sale30.022,33970,2096,555Mar 23 06:52 PM